share_log

Revance Therapeutics | 10-K: FY2022 Annual Report

SEC ·  Mar 1, 2023 05:22
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more